Array BioPharma (ARRY +1.8%) and Pfizer (PFE -0.3%) will collaborate on clinical trials assessing the safety and efficacy of several immunotherapy combinations to treat cancer. Studies will evaluate the combination of Array's MEK inhibitor binimetinib and Pfizer's PARP inhibitor talazoparib and PD-L1 inhibitor avelumab (being co-developed with Merck KGaA).
A Phase 1b trial will evaluate doublet and triplet approaches across a range of tumor types with an initial focus on non-small cell lung cancer and pancreatic cancer. The study should commence by Q3 2018.
Pfizer will sponsor the study while Array will supply product.
Subscribe for full text news in your inbox